Intravitreal ranibizumab with delayed laser photocoagulation effectively treated severe zone I and posterior zone II retinopathy of prematurity, according to findings presented at the Association for Research in Vision and Ophthalmology meeting.
“This can be used in practice immediately. Ranibizumab has been approved by the FDA for intravitreal use and planned laser photocoagulation has been long approved and used for the treatment of retinopathy of prematurity,” Irina De la Huerta, MD, PhD, vitreoretinal surgeon, adult and pediatric retinal specialist and an assistant professor at
Uncategorized